FBInvestor
Stocks / Arbutus Biopharma Corp
Institutional Ownership

Arbutus Biopharma Corp

CUSIP 03879J100COMABUSQ1 2026

13D / 13G Filings
24
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
29.1%
Max % of class reported
Institutional Holders
160
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

24 filings · latest Feb 17, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 17, 2026Two Seas Capital LP13G/A6.5%SEC
2Feb 11, 2026Morgan Stanley13G/A13.5%25.91MSEC
3Aug 13, 2025Two Seas Capital LP13G5.4%SEC
4Feb 25, 2025Roivant Sciences Ltd.13D/A20.5%SEC
5Feb 21, 2025Whitefort Capital Master Fund, LP13D/A7.0%SEC
6Feb 18, 2025Roivant Sciences Ltd.13D/A20.5%SEC
7Feb 3, 2025Morgan Stanley13G/A11.4%21.52MSEC
8Nov 14, 2024Two Seas Capital LP13G/A4.4%8.39MSEC
9Jun 10, 2024Morgan Stanley13G10.3%19.39MSEC
10May 17, 2024Whitefort Capital Management, LP13D/A6.8%12.87MSEC

14 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Arbutus Biopharma Corp.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Morgan Stanley25.89M$116.51M
2Two Seas Capital LP18.56M$83.51M
3Whitefort Capital Management, LP14.93M$67.19M
4Blackrock, Inc.12.97M$58.35M
5Rubric Capital Management LP6.63M$29.82M
6State Street Corp6.34M$28.54M
7Barclays PLC4.32M$19.42M
8Geode Capital Management, LLC3.77M$16.98M
9Adar1 Capital Management, LLC3.13M$14.10M
10Adage Capital Partners Gp, L.L.C.2.66M$11.99M